References
- HerendeenJMLindleyCUse of NSAIDs for the chemoprevention of colorectal cancerAnn Pharmacother200337111664167414565811
- HilmiIGohKLChemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugsChin J Dig Dis2006711616412030
- BusPJVerspagetHWLamersCBGriffioenGChemoprevention of colorectal cancer by non-steroidal anti-inflammatory drugsScand J Gastroenterol Suppl200023210110411232485
- FortJCelecoxib, a COX-2 – specific inhibitor: the clinical dataAm J Orthop1999283 suppl131810193998
- ArberNEagleCJSpicakJPreSAP Trial InvestigatorsCelecoxib for the prevention of colorectal adenomatous polypsN Engl J Med2006355988589516943401
- DaviesNMGuddeTWde LeeuwMACelecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposisExpert Opin Pharmacother20012113915211336575
- SteinbachGLynchPMPhillipsRKThe effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposisN Engl J Med2000342261946195210874062
- LeeYKimWHongSColon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantagesEur J Pharmacol2014726495624462351
- CuzzocreaSMazzonESerrainoICelecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in ratsEur J Pharmacol200143119110211716847
- El-MedanyAMahgoubAMustafaAArafaMMorsiMThe effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in ratsEur J Pharmacol20055071–329129915659320
- BrophyJMCardiovascular risk associated with celecoxibN Engl J Med20053522526482650 author reply 2648–265015972876
- CaldwellBAldingtonSWeatherallMShirtcliffePBeasleyRRisk of cardiovascular events and celecoxib: a systematic review and meta-analysisJ R Soc Med200699313214016508052
- OviedoJASchroyPC3rdDoes celecoxib use increase the risk of cardiovascular events?Gastroenterology200512941348135016230088
- SolomonSDMcMurrayJJPfefferMAAdenoma Prevention with Celecoxib (APC) Study InvestigatorsCardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionN Engl J Med2005352111071108015713944
- JungYKimYMWhat should be considered on design of a colon-specific prodrug?Expert Opin Drug Deliv20107224525820095945
- RubinsteinAMicrobially controlled drug delivery to the colonBiopharm Drug Dispos19901164654752207298
- SinhaVRKumriaRColonic drug delivery: prodrug approachPharm Res200118555756411465408
- SinhaVRKumriaRPolysaccharides in colon-specific drug deliveryInt J Pharm20012241–2193811472812
- ShrivastavaPKShrivastavaSKDextran carrier macromolecule for colon specific delivery of celecoxibCurr Drug Deliv20107214415120158488
- LeeYKimJKimHN-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic propertiesJ Pharm Sci201210151831184222334096
- KimHKongHChoiBMetabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel diseasePharm Res20052291499150916132362
- BuerkleMALehrerSSohnHYConzenPPohlUKrotzFSelective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivoCirculation2004110142053205915451781
- MehvarRDextrans for targeted and sustained delivery of therapeutic and imaging agentsJ Control Release200069112511018543
- FriendDRReview article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel diseaseAliment Pharmacol Ther19981275916039701522